PDX model details
PDX ID | 201.2A |
---|---|
Host Strain(and Source) | NSG Source: Monash University |
Host Strain Immune system Humanized | NO |
Host Type | Testosterone supplemented |
Graft Site | Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
31 |
Average PDX Generation Time (days +/- SEM) | 39 ± 2 |
Tumor preparation | Tumor solid |
Tumor Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
Tumor confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
Passage QA performed | Routine QA every 2-3 passages |
Associated meta data | |
PDX model availability | Yes (fixed, frozen) |
Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
Pubmed ID | 34413304; 30049486 |
Markers | 201.2A |
---|---|
AR | N |
PSA | N |
PSMA | N |
NE | Y |
ERG | N |
No information in CNV Table
Clinical Information
Sample Number | 201.2A |
---|---|
Sample Site | Lung |
Sample source | Autopsy |
Pathology Tumor Diagnosis | Adenocarcinoma |
Gleason Score | None |
Primary Gleason Score | None |
Secondary Gleason Score | None |
Tertiary Gleason Score | None |
ISUP Grade Group | |
Tumor Grade | |
D'Amico Risk Classification | |
Tumor Volume (in cc) | 0.0 |
Treatment Prior to Specimen Collection | ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
Patient Information
Patient Number | 201 |
---|---|
Sex | Male |
Diagnosis | Prostate Cancer |
PSA at diagnosis (ng/mL) | NA |
Consent to share data | |
Patient Tumor Collection (Current Model) | |
---|---|
Tumour sample ID | 201.2A |
Patient Age (binned in 5 year age groups) | 70-74 |
No information in Mutation Table
No information in Drug dosing Table